Compare Adaptive Biotechnologies Corp (ADPT) vs American Financial Group Inc (AFG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs American Financial Group Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while American Financial Group Inc trades at $141.21 (market cap $11.86B). The key difference: American Financial Group Inc is far larger — about 3.6× Adaptive Biotechnologies Corp's market cap, and American Financial Group Inc pays a 2.46% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | AFG | |
|---|---|---|
Market Cap | $3.33B | $11.86B |
Sector | Health | Financials |
52-Week High | $22.37 | $148.71 |
52-Week Low | $10.24 | $122.42 |
Enterprise Value | $3.19B | $12.33B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
AFG trades at $142.80, up 0.04% with a bullish technical outlook. The stock shows strong profitability with 10.84% net margin and 19.38% ROE, though Q1 2026 earnings missed estimates. Recent dividend declarations of $0.88 per share highlight shareholder returns. Analyst consensus is mixed with 41% buy ratings and a $149 price target, representing 4.3% upside from current levels.
AFG offers moderate upside potential with solid fundamentals and consistent dividends, but faces execution risks after recent earnings miss. The insurance sector exposure provides stability, though competitive pressures and regulatory changes remain key watchpoints for investors seeking steady returns with income generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →
